MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

20.63 -0.19

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.31

Максимум

20.75

Ключови измерители
By Trading Economics
Приходи	-14M -50M
Продажби	12M 128M
Марж на печалбата	-39.506
Служители	1,784
EBITDA	-17M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+68.56% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	105M 2.3B
Предишно отваряне	20.82
Предишно затваряне	20.63

Настроения в новините

By Acuity

42%

58%

146 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9.04.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9.04.2026 г., 23:14 ч. UTC

Пазарно говорене

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9.04.2026 г., 23:14 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

9.04.2026 г., 23:07 ч. UTC

Пазарно говорене

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9.04.2026 г., 22:54 ч. UTC

Пазарно говорене

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9.04.2026 г., 22:31 ч. UTC

Значими събития в новините

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9.04.2026 г., 22:31 ч. UTC

Значими събития в новините

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9.04.2026 г., 20:57 ч. UTC

Значими събития в новините

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

9.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.04.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Rowan Digital Infrastructure Announces Strategic Recapitalization

9.04.2026 г., 20:25 ч. UTC

Придобивния, сливания и поглъщания

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.04.2026 г., 19:30 ч. UTC

Значими събития в новините

How Digital Currencies Have Helped Iran -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

68.56% нагоре

12-месечна прогноза

Среден 34.96 USD 68.56%

Висок 47 USD

Нисък 21.8 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

146 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.